Literature DB >> 18086899

Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia.

Marcin W Wlodarski1, Zachary Nearman, Anna Jankowska, Nina Babel, Jennifer Powers, Patrick Leahy, Hans-Dieter Volk, Jaroslaw P Maciejewski.   

Abstract

T cell large granular lymphocyte leukemia (T-LGL) is a chronic clonal lymphoproliferation of CTL. In many ways, T-LGL clones resemble terminal effector CTL, including down-modulation of CD28 and overexpression of perforin, granzymes, and CD57. We studied the transcriptome of T-LGL clones and compared it with healthy CD8+CD57+ effector cells as well as CD8+CD57- populations. T-LGL clones were sorted based on their TCR variable beta-chain restriction, and controls were obtained by pooling cell populations from 14 donors. Here, we focus our analysis on immunological networks, as immune mechanisms play a prominent role in the etiology of bone marrow failure in T-LGL. Informative genes identified by expression arrays were studied further in an independent cohort of patients using Taqman PCR, ELISA assays, and FACS analysis. Despite a strikingly similar gene expression profile between T-LGL clones and their healthy counterparts, important phenotypic differences were identified, including up-modulation of TNFRS9, myeloid cell leukemia sequence 1, IFN-gamma, and IFN-gamma-related genes, and several integrins/adhesion molecules. In addition, T-LGL clones were characterized by an overexpression of chemokines and chemokine receptors that are typically associated with viral infections (CXCL2, Hepatitis A virus cellular receptor 1, IL-18, CCR2). Our studies suggest that immunodominant LGL clones, although phenotypically similar to effector CTL, show significantly altered expression of a number of genes, including those associated with an ongoing viral infection or chronic, antigen-driven immune response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18086899      PMCID: PMC2629660          DOI: 10.1189/jlb.0107073

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  79 in total

1.  Constitutive expression of cytotoxic proteases and down-regulation of protease inhibitors in LGL leukemia.

Authors:  Ravi Kothapalli; Ratna D Bailey; Irina Kusmartseva; Shrikant Mane; P K Epling-Burnette; Thomas P Loughran
Journal:  Int J Oncol       Date:  2003-01       Impact factor: 5.650

2.  Monoclonal T-cell expansions in asymptomatic individuals and in patients with large granular leukemia consist of cytotoxic effector T cells expressing the activating CD94:NKG2C/E and NKD2D killer cell receptors.

Authors:  Valerie Bigouret; Till Hoffmann; Lionel Arlettaz; Jean Villard; Marco Colonna; André Ticheli; Alois Gratwohl; Kaveh Samii; Bernard Chapuis; Nathalie Rufer; Eddy Roosnek
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

Review 3.  Apoptosis in the development and maintenance of the immune system.

Authors:  Joseph T Opferman; Stanley J Korsmeyer
Journal:  Nat Immunol       Date:  2003-05       Impact factor: 25.606

4.  T cell homeostatic proliferation elicits effective antitumor autoimmunity.

Authors:  Wolfgang Dummer; Andreas G Niethammer; Roberto Baccala; Brian R Lawson; Norbert Wagner; Ralph A Reisfeld; Argyrios N Theofilopoulos
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

5.  Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia.

Authors:  Jin Hong Liu; Sheng Wei; Thierry Lamy; Yongxiang Li; P K Epling-Burnette; Julie Y Djeu; Thomas P Loughran
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

Review 6.  Clinical features of large granular lymphocyte leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Semin Hematol       Date:  2003-07       Impact factor: 3.851

Review 7.  Survival signals in leukemic large granular lymphocytes.

Authors:  P K Epling-Burnette; Thomas P Loughran
Journal:  Semin Hematol       Date:  2003-07       Impact factor: 3.851

8.  T-cell large granular lymphocyte leukemia is characterized by massive TCRBV-restricted clonal CD8 expansion and a generalized overexpression of the effector cell marker CD57.

Authors:  J Joseph Melenhorst; Rhoda Eniafe; Dean Follmann; Jeffrey Molldrem; Martha Kirby; Frank El Ouriaghli; A John Barrett
Journal:  Hematol J       Date:  2003

Review 9.  Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases.

Authors:  Harald Neumann; Isabelle M Medana; Jan Bauer; Hans Lassmann
Journal:  Trends Neurosci       Date:  2002-06       Impact factor: 13.837

10.  Phenotypic and functional separation of memory and effector human CD8+ T cells.

Authors:  D Hamann; P A Baars; M H Rep; B Hooibrink; S R Kerkhof-Garde; M R Klein; R A van Lier
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

View more
  13 in total

1.  Autoreactive T effector memory differentiation mirrors β cell function in type 1 diabetes.

Authors:  Lorraine Yeo; Alyssa Woodwyk; Sanjana Sood; Anna Lorenc; Martin Eichmann; Irma Pujol-Autonell; Rosella Melchiotti; Ania Skowera; Efthymios Fidanis; Garry M Dolton; Katie Tungatt; Andrew K Sewell; Susanne Heck; Alka Saxena; Craig A Beam; Mark Peakman
Journal:  J Clin Invest       Date:  2018-07-16       Impact factor: 14.808

2.  T-cell clones of uncertain significance are highly prevalent and show close resemblance to T-cell large granular lymphocytic leukemia. Implications for laboratory diagnostics.

Authors:  Min Shi; Horatiu Olteanu; Dragan Jevremovic; Rong He; David Viswanatha; Heidi Corley; Pedro Horna
Journal:  Mod Pathol       Date:  2020-05-13       Impact factor: 7.842

Review 3.  T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias.

Authors:  Rebecca J Watters; Xin Liu; Thomas P Loughran
Journal:  Leuk Lymphoma       Date:  2011-07-13

4.  Primary autoimmune myelofibrosis: a case report and review of the literature.

Authors:  Yasmin Abaza; C Cameron Yin; Carlos E Bueso-Ramos; Sa A Wang; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2016-11-09       Impact factor: 2.490

Review 5.  Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia.

Authors:  HeeJin Cheon; Karolina H Dziewulska; Katharine B Moosic; Kristine C Olson; Alejandro A Gru; David J Feith; Thomas P Loughran
Journal:  Curr Hematol Malig Rep       Date:  2020-04       Impact factor: 3.952

6.  TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia.

Authors:  Jun Yang; Francis R LeBlanc; Shubha A Dighe; Cait E Hamele; Thomas L Olson; David J Feith; Thomas P Loughran
Journal:  Blood       Date:  2018-04-26       Impact factor: 22.113

Review 7.  Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias.

Authors:  Kazuo Oshimi
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

8.  Dysregulated signaling, proliferation and apoptosis impact on the pathogenesis of TCRγδ+ T cell large granular lymphocyte leukemia.

Authors:  Martine J Kallemeijn; Dick de Ridder; Joyce Schilperoord-Vermeulen; Michèle Y van der Klift; Yorick Sandberg; Jacques J M van Dongen; Anton W Langerak
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

9.  T-Cell Large Granular Lymphocyte Leukemia in a Patient With Rheumatoid Arthritis.

Authors:  Sara Naji Rad; Behnam Rafiee; Gagan Raju; Mahdis Solhjoo; Prachi Anand
Journal:  J Investig Med High Impact Case Rep       Date:  2020 Jan-Dec

10.  Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder really two distinct diseases?

Authors:  Renato Zambello; Antonella Teramo; Cristina Gattazzo; Gianpietro Semenzato
Journal:  Transl Med UniSa       Date:  2014-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.